Skip to main content
Log in

Why Japan lacks a vibrant biotech industry

  • Correspondence
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

An Author Correction to this article was published on 04 June 2024

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Change history

References

  1. Ezell, S. How Japan squandered its biopharmaceutical competitiveness: a cautionary tale. https://itif.org/publications/2022/07/25/how-japan-squandered-its-biopharmaceutical-competitiveness-a-cautionary-tale/ (Information Technology and Innovation Foundation, 2022).

  2. Vital Transformation, LLC. The US Ecosystem for Medicines. https://vitaltransformation.com/wp-content/uploads/2022/12/Where-do-new-medicines-originate_FINAL2022_12_05.pdf (2022).

  3. Venture Enterprise Center. VEC yearbook 2023. https://www.vec.or.jp/en (2023).

  4. Startup Genome. The global startup ecosystem report, GSER 2021. https://startupgenome.com/report/gser2021 (2021).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark Kessel.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kessel, M., Vickrey, C. Why Japan lacks a vibrant biotech industry. Nat Biotechnol 42, 694 (2024). https://doi.org/10.1038/s41587-024-02227-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-024-02227-x

  • Springer Nature America, Inc.

Navigation